$17,754.34 research Payment -- Biogen to Dr. Stephanie King
Biogen's $17,754.34 Research Payment to Psychiatry Specialist Dr. Stephanie King for Skyrizi
This page provides a detailed analysis of a $17,754.34 research payment from Biogen to Dr. Stephanie King. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $17,754.34 |
| Payment Type | research |
| Payment Nature | Research |
| Pharmaceutical Company | Biogen |
| Physician | Dr. Stephanie King |
| NPI Number | 1642734339 |
| Physician Specialty | Psychiatry |
| Location | City, IN |
| Date of Payment | 2024-10-03 |
| Related Drug/Device | Skyrizi |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Biogen made a $17.8K research payment to Stephanie King, a Psychiatry specialist in City, IN. The payment was associated with Skyrizi. Biogen paid Dr. Stephanie King $17,754.34 for research related to Skyrizi. The payment was made on October 3, 2024, and is categorized under 'research'. Dr. King's specialty is Psychiatry, and the payment is associated with the drug Skyrizi.
Patient Guidance: What This Payment Means for You
This payment is for research activities and may involve studies related to the drug Skyrizi. Consult your doctor for details about any research you may be participating in. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Research payments to psychiatrists can vary widely depending on the scope and duration of the study. This specific amount should be considered in the context of similar research grants within the psychiatry field.
Regulatory Context: Sunshine Act Requirements
This payment is reported under the Sunshine Act, requiring disclosure of financial relationships between drug and device manufacturers and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- biogen
- research-payment
- psychiatry
- skyrizi
- healthcare-professional-payment
- cms-open-payments
Understanding research Payments
Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.
Frequently Asked Questions About This Payment
What was this $17.8K payment for?
This was a research payment of $17.8K from Biogen to Stephanie King, categorized as "Research". It was associated with Skyrizi. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Stephanie King accept pharmaceutical money?
Yes, Stephanie King received this $17.8K payment from Biogen. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Stephanie King's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this research payment?
A research payment of $17.8K typically funds clinical studies and is considered standard academic activity. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Psychiatry?
To compare this payment against Psychiatry averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Psychiatry physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Stephanie King's relationship with Biogen?
The payment amount is a specific figure, $17,754.34, indicating a defined research project or agreement. This $17.8K research payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Psychiatry?
The payment type is 'research', which is a common category for pharma-industry collaborations with healthcare professionals.
What should patients do after learning about this payment?
This payment is for research activities and may involve studies related to the drug Skyrizi. Consult your doctor for details about any research you may be participating in.
What else should I know about this research payment?
The drug mentioned, Skyrizi, is a specific product from Biogen, suggesting the research is likely focused on this medication.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.